The Cochlear Ltd share price has climbed higher into the green in Wednesday morning trade.
Today's increase means the shares have now rebounded around 53% from a 10-year low of just $90 each in late April.
The Cochlear share price fell around 20% after the company released its half-year results in February, and the shares crashed another 41% in a day in late April after the company downgraded its guidance figures.
Looking ahead to FY27, Cochlear expects low-single-digit constant currency revenue growth and an underlying net profit between $330 million and $350 million.
4 sentences from our version of the report,
chosen to cover it. Nothing here is written; every line is in the article below.
How
Summarized version
The Cochlear Ltd share price has climbed higher into the green in Wednesday morning trade. In July, the company confirmed its hearing implant systems will continue to be imported into the US duty-free after the US Government released its findings from a series of Section 301 investigations.
Headline check
All two things this headline claims are in the report.
Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. How this is checked
The article, shortened and in plain language
The Cochlear Ltd share price has climbed higher into the green in Wednesday morning trade.
The ASX healthcare shares are up over 1% to $137.95 a piece.
Today's increase means the shares have now rebounded around 53% from a 10-year low of just $90 each in late April.
The recovery has been consistent, but there is a long way for the shares to go before they return to pre-2026 levels following a series of investor sell-offs earlier this year.
Cochlear has suffered from some strong headwinds, including a sector-wide rotation away from ASX healthcare shares this year and some disappointing financial updates.
The Cochlear share price fell around 20% after the company released its half-year results in February, and the shares crashed another 41% in a day in late April after the company downgraded its guidance figures.
In July, the company confirmed that its hearing implant systems will continue to be imported into the US duty-free after the US Government released its findings from a series of Section 301 investigations.
Looking ahead to FY27, Cochlear expects low-single-digit constant currency revenue growth and an underlying net profit between $330 million and $350 million.
Shortened to 1 minute
of reading, this version reads 11.4 on the Niral Score.
You are reading our version, not theirs.
This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with
verdicts and loaded words taken out. Plain description stays, and so do adjectives
that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations
are theirs — quotations are never edited — and the indicators beside it measure
this version. Hover or tap Adjectives to see every one left in the text.
How this outlet filed it, and how we rewrote it
No other newsroom we read has filed on this event, so there is nothing to compare it with yet.
Readers can ask a question about this story here.
Questions and answers are for subscribers.
Sign in
to read them.
Comments are read before they appear where anything in them needs a person to look.
Nothing posted here is ever deleted; a comment taken down keeps its text and the reason,
so the decision can be looked at again. How this works